mtx-474
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2024 (NCT06535841)
Timeline
Indications
Studied for
Mechanism of action
- Ephrin-B2INHIBITOR
EFNB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287670 | Phase 2 | Dec 31, 2025 | Medeor Therapeutics, Inc. |
| NCT06535841 | Phase 1 | Jul 10, 2024 | Medeor Therapeutics, Inc., Nucleus Network Ltd, ProPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medeor Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2024 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2024 |
| ProPharma | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1